Leaflet MEDABON 200mg / 0.2mg tablets and vaginal tablets
Indicated for: medical termination of pregnancy
Route of administration: vaginal
Substance: mifepristone + misoprostol (hormone + vasodilator)
ATC: G03XB01 (Genito urinary system and sex hormones | Other sex hormones and modulators of the genital system | Progesterone receptor modulators)
This medicine may cause dizziness or vertigo.
Effective contraception is required during treatment.
Do not use this medicine during pregnancy.
May lower blood pressure and increase the risk of falls.
Use during breastfeeding only on medical advice.
This medicine may affect fetal development.
The combination of Mifepristone + misoprostol is used for terminating early pregnancies, typically up to 10 weeks of gestation. Mifepristone blocks the effects of progesterone, while Misoprostol stimulates uterine contractions, completing the medical abortion process.
The medications are administered orally or vaginally, according to a specific regimen, under medical supervision. This combination is highly effective in terminating pregnancies.
Side effects may include nausea, vomiting, abdominal cramps, diarrhea, and vaginal bleeding. In rare cases, severe complications such as infections or hemorrhage may occur. Close monitoring is essential.
Consult your doctor to discuss the benefits and risks of treatment with this combination. Use must occur exclusively under medical supervision.
General data about MEDABON 200mg / 0.2mg
- Substance: mifepristone + misoprostol
- Date of latest medicines list: 01-06-2026
- Product code: W59313001
- Concentration: 200mg / 0.2mg
- Pharmaceutical form: tablets and vaginal tablets
- Quantity: 1
- Product type: Original
- Price: 301.83 RON
- Prescription status: P-RF - Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for mifepristone + misoprostol
Concentrations available for mifepristone + misoprostol
- 200mg/0.2mg
- 600mg/400mcg